3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroendocrine Tumors
5
Gastro-enteropancreatic neuroendocrine tumor
2
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
18
Nivolumab
13
avelumab
10
Ipilimumab
7
Specimen Handling
6
cemiplimab
5
atezolizumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
Radiotherapy
3
Cyclophosphamide
3
prednylidene
2
poly ICLC
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
deltacortene
2
aldesleukin
2
Radiosurgery
2
Prednisone
2
Interleukin-2
2
Immunoglobulin G
2
Docetaxel
2
CTLA-4 Antigen
2
Bevacizumab
2
tocilizumab
1
talimogene laherparepvec
1
sargramostim
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
1 year
×
Clear all
No trials found.